- Home
- LGVN vs NVNO Comparison
LGVN vs NVNO Comparison
Compare LGVN & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- NVNO
- Stock Information
- Founded
- LGVN 2014
- NVNO 1987
- Country
- LGVN United States
- NVNO United States
- Employees
- LGVN N/A
- NVNO N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- NVNO Medical/Dental Instruments
- Sector
- LGVN Health Care
- NVNO Health Care
- Exchange
- LGVN Nasdaq
- NVNO Nasdaq
- Market Cap
- LGVN 16.6M
- NVNO 16.7M
- IPO Year
- LGVN 2021
- NVNO N/A
- Fundamental
- Price
- LGVN $0.79
- NVNO $0.78
- Analyst Decision
- LGVN Strong Buy
- NVNO
- Analyst Count
- LGVN 2
- NVNO 0
- Target Price
- LGVN $6.50
- NVNO N/A
- AVG Volume (30 Days)
- LGVN 496.8K
- NVNO 2.3M
- Earning Date
- LGVN 11-11-2025
- NVNO 10-30-2025
- Dividend Yield
- LGVN N/A
- NVNO N/A
- EPS Growth
- LGVN N/A
- NVNO N/A
- EPS
- LGVN N/A
- NVNO N/A
- Revenue
- LGVN $2,073,000.00
- NVNO N/A
- Revenue This Year
- LGVN N/A
- NVNO N/A
- Revenue Next Year
- LGVN N/A
- NVNO N/A
- P/E Ratio
- LGVN N/A
- NVNO N/A
- Revenue Growth
- LGVN 68.67
- NVNO N/A
- 52 Week Low
- LGVN $0.63
- NVNO $0.67
- 52 Week High
- LGVN $2.48
- NVNO $5.70
- Technical
- Relative Strength Index (RSI)
- LGVN 37.95
- NVNO 20.18
- Support Level
- LGVN $0.78
- NVNO $0.67
- Resistance Level
- LGVN $0.85
- NVNO $1.12
- Average True Range (ATR)
- LGVN 0.05
- NVNO 0.07
- MACD
- LGVN 0.02
- NVNO 0.06
- Stochastic Oscillator
- LGVN 46.30
- NVNO 30.75
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.